Hormone replacement therapy for prevention: more evidence, more pessimism

Editorial

Diana B Petitti. JAMA. 2002.

. 2002 Jul 3;288(1):99-101.

doi: 10.1001/jama.288.1.99.

No abstract available

Comment on

Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).
Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N; HERS Research Group. Grady D, et al. JAMA. 2002 Jul 3;288(1):49-57. doi: 10.1001/jama.288.1.49. JAMA. 2002. PMID: 12090862 Clinical Trial.
Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).
Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E, Hunninghake D; HERS Research Group. Hulley S, et al. JAMA. 2002 Jul 3;288(1):58-66. doi: 10.1001/jama.288.1.58. JAMA. 2002. PMID: 12090863 Clinical Trial.